Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

PCSK9 and infection: A potentially useful or dangerous association? (CROSBI ID 275296)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Khademi, Farzad ; Momtazi-borojeni, Amir Abbas ; Reiner, Željko ; Banach, Maciej ; Al-Rasadi, Khalid Al ; Sahebkar, Amirhossein PCSK9 and infection: A potentially useful or dangerous association? // Journal of cellular physiology, 233 (2017), 4; 2920-2927. doi: 10.1002/jcp.26040

Podaci o odgovornosti

Khademi, Farzad ; Momtazi-borojeni, Amir Abbas ; Reiner, Željko ; Banach, Maciej ; Al-Rasadi, Khalid Al ; Sahebkar, Amirhossein

engleski

PCSK9 and infection: A potentially useful or dangerous association?

Elevated plasma low-density lipoprotein- cholesterol (LDL-C) concentration is the most important risk factor for atherosclerotic cardiovascular diseases (CVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ubiquitously expressed serine proteinase which plays a key role in cholesterol metabolism, but has been found to be implicated in some other lipid-independent physiological processes. In this review, the role of PCSK9 was evaluated not only concerning lipid metabolism but also hepatitis C virus (HCV) infection, bacterial infections/sepsis, and septic shock. Collected data from clinical trials revealed that treatment with PCSK9 inhibitors has beneficial effects in lowering LDL-C via inhibition of LDL-receptors (LDL-R), an antiviral effect on HCV infection via down-regulating the surface expression of LDL-R and CD81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock by down-regulation of hepatocyte LDL-R. On the other hand, PCSK9 inhibition by therapeutic fully humanized antibodies has positive effects in reducing elevated LDL-C. However, their safety and tolerability is an important issue which has to be taken into consideration

LDL receptor ; PCSK9 ; cholesterol ; hepatitis C virus ; infection

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

233 (4)

2017.

2920-2927

objavljeno

0021-9541

10.1002/jcp.26040

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost